Диссертация (1140673), страница 16
Текст из файла (страница 16)
Kaheinen P., Haikala H. Increases in diastolic coronary flow bylevosimendan and pinacidil are differently mediated through opening of theATP-sensitive potassium channels. JACC1998; 31 (Suppl. С): 154С.73. Kaheinen P., Pollesello P., Levijoki J., Haikala H. Levosimendan increasesdiastolic coronary flow in isolated guinea-pig heart by openingATPsensitive potassium channels. Journal of Cardiovascular Pharmacology2001; 37: 367-374.74. Karlsson M., Wikberg T. Determination of levosimendan in human urinewith high performance liquid chromatography and UV- detection -study №.3001011.
Internal report: Orion-Farmos; 1995 September 1.Report №.:CR95031200237.75. Kersten J.R., Montgomery M.W., Pagel P.S., Warltier D.C. Levosimendan, anew positive inotropic drug, decreases myocardial infarct size viaactivation of К (ATP) channels. Anesth Analg 2000; 90: 5-11.10176. Kivikko M., Antila S., Eha J.etal. Pharmacodynamics and safety of a newcalcium sensitizer, levosimendan, and its metabolites during anextendedinfusion in patients with severe heart failure.
J Clin Pharmacol 2002; 42:43-51.77. Kivikko M., Lehtonen L., Colucci W.S., on Behalf of Study Investigators.Sustained hemodynamic affects of intravenous levosimendan. Circulation2003; 107: 81-86.78. Kleber F., Sundberg S. Effects of a calcium sensitizing drug, levosimendan,on diastolic function and on stunned/hibernating myocardium after PTC A.Internal report: Orion Pharma; 1999 June 16. Report №.: 3001016.79. Kristof E., Szigeti G., Papp Z.
et al. Cardiac responses to calcium sensitizersand isoproterenol in intact guinea pig hearts: effects on cyclic AMP levels,protein phosphorylation, myoplasmic calcium concentration, and leftventricular function. Ann N Y Acad Sci 1998; 853: 316-319.80. Lahtinen P., Pitkänen O., Pölönen P., at.al. Levosimendan reduces heartfailure after cardiac surgery – a prospective, randomised, placebocontrolled trial // Crit.
Care Med. 2011. Vol. 39. P. 2263–2270).81. Landoni G, M.D., Lomivorotov V., M.D., Ph.D., Alvaro G et al., andAlberto Zangrillo, M.D., for the CHEETAH Study Group*. Levosimendanfor Hemodynamic Support after Cardiac Surgery N Engl J Med 2017;376:2021-2031May 25, 2017DOI: 10.1056/NEJMoa161632582. Landoni G., Augoustides J.G., Guarracino F., et al: Mortality reduction incardiac anesthesia and intensive care: Results of the Firs InternationalConsensus Conference. Acta Anaesthesiol.
Scand. 55:259-266, 201183. Landoni G., Biondi-Zoccai G., Greco M., et al: Effects of levosimendan onmortality and hospitalization. A meta-analysis of randomized controlledstudies. Crit Care Med 40:634-646, 201284. Landoni G., Mizzi A., Biondi-Zoccai G., et al. Reducing Mortality inCardiac Surgery With Levosimendan: A Meta-analysis of Randomized102Controlled Trials, Journal of Cardiothoracic and Vascular Anesthesia, Vol24, No 1 (February), 2010: pp 51-5785. Levin R., Degrange M, Del Mazo C., et al. Preoperative levosimendandecreases mortality and the development of low cardiac output in high-riskpatients with severe left ventricular dysfunction undergoing coronary arterybypass grafting with cardiopulmonary bypass, Exp.
Clin. Cardiol. 17(2012) 125–130.86. Lilleberg J., Antila S., Karlsson M. et al. Pharmacokinetics andpharmacodynamics of simendan, a novel calcium sensitizer, in healthyvolunteers. Clin Pharmacol Ther 1994; 56: 554-563.87. Lilleberg J., Nieminen M.S., Akkila J. et al. Effects of a new calciumsensitizer, levosimendan, on haemodynamics, coronary blood flow andmyocardial substrate utilization early after coronary artery bypass grafting.Eur Heart J1998; 19: 660-668.88. Lilleberg J., Sundberg S., Nieminen M.S.
Dose-range study of a newcalcium sensitizer, levosimendan, in patients with left ventriculardysfunction. J Cardiovasc Pharmacol 1995; 26 (suppl. 1): S63-S69.89. Lilleberg J., SundbergS., Nieminen M.S. Dose-range study of a new calciumsensitizer, levosimendan, in patients with left ventricular dysfunction.
JCardiovasc Pharmacol 1995; 26 Suppl. 1: 63-69.90. Lochner A., Colesky F., Genade S., Effect of a calcium-sensitizing agent,levosimendan, on the postcardioplegic inotropic response of themyocardium. Cardiovasc. Drugs Ther. 2000; 14:271–81.91.
Maharaj R., Metaxa V., Levosimendan and mortality after coronaryrevascularisation: a meta-analysis of randomised controlled trials, Crit.Care 15 (2011) R140.92. McAlister FA, Teo KK, Taher M et al. Insights into the contemporaryepidemiology and outpatient management of congestive heart failure. AmHeart J. 1999;138 (1 Pt 1):87–94.10393. Mebazaa A . American Heart Association, Annual Scientific Session.
Dallas,TX; 2005. The SURVival of Patients with Acute Heart Failure in Need ofIntraVEnous Inotropic Support (SURVIVE) trial. Late-breaking ClinicalTrials. 13–16 November.94. Mebazaa A, Parissis J, Porcher R, et al. Short-term survival by treatmentamong patients hospitalized with acute heart failure: the global ALARMHF registry using propensity scoring methods. Intensive Care Med. 2011Feb;37(2):290-30195. Mebazaa A., Nieminen M.S., Packer M., et al.: Levosimendan vsdobutamine for patients with acute decompensated heart failure: theSURVIVED Randomized Trial. JAMA 2007; 297:1883-91.96.
Mehta R, M.D., Leimberger J, Ph.D., Sean van Diepen, M.D., et al. M.H.S.,for the LEVO-CTS Investigators* Levosimendan in Patients with LeftVentricular Dysfunction Undergoing Cardiac Surgery,N Engl J Med2017; 376:2032-2042May 25, 2017DOI: 10.1056/NEJMoa161621897. Moiseyev V.S., Poder P., Andrejevs N. et al. Safety and efficacy of a novelcalcium sensitizer, levosimendan, in patients with left ventricular failuredue to an acute myocardial infarction. A randomized, placebo-controlled,double-blind study (RUSSLAN).
Eur Heart J 2002; 23:1422-1432.98. Muller C.A., Hofmann D., McCarthy J. et al. Effects of the calciumsensitiser levosimendan in a pig-model of ischemia and reperfusion. J MolCell Cardiol 1998; 30: A80.99. Nesher N, Alghamdi AA, Singh SK.
et al. Troponin after cardiac surgery: apredictor or a phenomenon? Ann Thorac Surg. 2008;85:1348–1354100. Nicklas J.M., Monsur J.C., Bleske B.E. Effects of intravenous levosimendanon plasma neurohormone levels in patients with heart failure: relation tohemodynamic response. Am J Cardiol 1999; 83:12(l)-15(l). 36. FiggittD.P., Gillies P.S., Goa K.L Levosimendan. Drugs 2001; 61: 613-627.104101. Nieminen M., Akkila J., Hasenfuss G. et al. Hemodynamic andneurohumoral effects of continuous infusion of levosimendan in patientswith congestive heart failure. JACC 2000; 36:1903-1912.102.
Nieminen M.S., LillebergJ., SundbergS. etal. Dose response study of acutei.v.levosimendaninhealthyvolunteers.Internalreport:OrionPharmaceutica; 1993 February. Report №.: 300101.103. Nieminen M.S., Sandell E-R, Vuorinen J., Lehtonen L. A multicenter dosefinding study on the effects of continuous infusion of levosimendan oncardiac output in patients with congestive heart failure. Internal report:Orion Pharma; 1998 October 26. Report №.: 300105.104. Niu Z.Z., Wu S.M., Sun W.Y., et al. Perioperative levosimendan therapy isassociated with a lower incidence of acute kidney injury after cardiacsurgery: a meta-analysis, J.
Cardiovasc. Pharmacol. 63 (2014) 107–112105. Owan TE, Hodge DO, Herges RM et al. Trends in prevalence and outcomeof heart failure with preserved ejection fraction. N Engl J Med. 2006;355(3):251–259.106. Packer M, Colucci WS, Fisher L at al.. Effect of Levosimendan on theShort-Term Clinical Course of Patients With Acutely DecompensatedHeart Failure. JCHF. 2013;1(2):103-111. doi:10.1016/j.jchf.2012.12.004107. Packer M., Carver J.R., Rodeheffer R.J., at al.: Effect of oral milrinone onmortality in severe chronic heart failure. The PROMISE Study ResearchGroup.
N Engl J Med 1991; 325:1468-75.108. Pagel P.S., Harkin СР., Hettrick D.A., Warltier D.C.. Levosimendan (OR1259), a myofilament calcium sensitizer, enhances myocardial contractilitybut does not alter isovolumic relaxation in conscious and anesthetized dogs.Anesthesiology 1994; 81: 974-987.109. Papp J.G., Pollesello P., Varro A.F., et al.
Effect of levosimendan andmilrinoneonregionalmyocardialischemia/reperfusion-inducedarrhythmias in dogs. J Cardiovasc Pharmacol Ther 2006; 11:129–35.105110. Papp Z., Edes I., Fruhwald S., et al: Levosimendan: Molecular mechanismsand clinical implications consensus of experts on the mechanisms of actionof levosimendan. Int J Cardiol., 2012111. Parissis J.T., Adamopoulos S., Antoniades C., et al.
Effects of levosimendanon circulating pro-inflammatory cytokines and soluble apoptosis mediatorsin patients with decompensated advanced heart failure. Am J Cardiol2004;93: 1309–12.112. Parissis J.T., Andreadou I., Markantonis S.L., et al. Effects of levosimendanon circulating markers of oxidative and nitrosative stress in patients withadvanced heart failure.
![](https://s.studizba.com/z.php?f=/templates/si/i/noavatar.png&w=100&h=100&t=1"){kind=avatar}
